Lee Yuchun's Form 4 filing
Vertex Pharmaceuticals Inc (VRTX) · filed Jan 19, 2023
- Accession no.
- 0001209191-23-004005
- Filed
- Jan 19, 2023
- Trade date
- Jan 17-18, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.39M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lee YuchunCIK 0001334365 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2023 | Common Stock | MOption exerciseAcquired | +4,000 | $72.14 | +$288,560 | 5,875 | Direct | |
| Jan 17, 2023 | Common Stock | SSaleDisposed | −4,000 | $312.03F2,F3 | −$1,248,120 | 1,875 | Direct | |
| Jan 18, 2023 | Common Stock | MOption exerciseAcquired | +442 | $72.14 | +$31,885.88 | 2,317 | Direct | |
| Jan 18, 2023 | Common Stock | SSaleDisposed | −442 | $312.17F2,F4 | −$137,979.14 | 1,875 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2023 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 16,000 | Direct | |
| Jan 18, 2023 | Common Stock | MOption exerciseDisposed | −442 | $0.00 | $0 | 15,558 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Referenced by the price of 2 transactions in Table I.
- F3
Open market sales reported on this line occurred at a weighted average price of $312.03 (range $312.00 to $312.14).
Referenced by the price of 1 transaction in Table I.
- F4
Open market sales reported on this line occurred at a weighted average price of $312.17 (range $312.00 to $312.53).
Referenced by the price of 1 transaction in Table I.